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Abstract. Rapidly progressive Alzheimer’s disease (rpAD) is a variant of AD distinguished by a rapid decline in cognition
and short disease duration from onset to death. While attempts to identify rpAD based on biomarker profile classifications
have been initiated, the mechanisms which contribute to the rapid decline and prion mimicking heterogeneity in clinical
signs are still largely unknown. In this study, we characterized prion protein (PrP) expression, localization, and interactome
in rpAD, slow progressive AD, and in non-dementia controls. PrP along with its interacting proteins were affinity purified
with magnetic Dynabeads Protein-G, and were identified using Q-TOF-ESI/MS analysis. Our data demonstrated a significant
1.2-fold decrease in di-glycosylated PrP isoforms specifically in rpAD patients. Fifteen proteins appeared to interact with PrP
and only two proteins3/4histone H2B-type1-B and zinc alpha-2 protein3/4were specifically bound with PrP isoform isolated
from rpAD cases. Our data suggest distinct PrP involvement in association with the altered PrP interacting protein in rpAD,
though the pathophysiological significance of these interactions remains to be established.
Keywords: Aldolase A, Alzheimer’s disease, co-immunofluorescence, co-immunoprecipitation, histone, myelin P2,
peroxiredoxin 1, prion, proteomics, synapsin, tubulin, zinc
INTRODUCTION
Alzheimer’s disease (AD) is a common form of
dementia affecting more than 37 million people
worldwide [1, 2]. The prevalence of slow progres-
sive AD (spAD) pathology is well studied [3, 4],
however, a subset of rapidly progressive AD (rpAD)
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cases mimicking prion diseases is emerging [5–9].
These rpAD cases show distinct clinical parameters
[5, 6, 9] and pathological features [10], though the
risk factors and pathological mechanisms leading to
heterogeneous progression rates and phenotypes of
AD are still not known [3].
In recent years, neuropathological similarities,
genetic acquaintances, and coexistence between AD
pathology and prion diseases have been reported [11].
Some studies report coexistence between prion pro-
tein (PrP) and amyloid- (A) in plaques [12, 13].
A genetic correlation and systematic meta-analysis
shows PRNP to be a gene potentially related to
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AD susceptibility [14] with Met/Val 129 polymor-
phism as a potential risk factor for early onset of
AD [13, 15, 16]. Interestingly, the cellular form of
PrP also appears to be a high-affinity receptor for
A oligomers [17–19], and a population of sol-
uble oligomers (Ao) was found to interact with
PrP in AD and cause behavioral impairment. The
coherence between the levels of Ao interacting
with PrP appears to have significance importance
in AD progression and PrP plays a pivotal role in
AD pathobiology [20]. Despite the fact that such
pathological and genetic links between AD and
PrP have been identified, there is no evidence of a
world-wide PrP-interacting risk factor involved in
the course of a slow or a rapid progression of the
disease.
In this study, we demonstrate that post-
translationally modified PrP isoforms are reduced
specifically in rpAD patients, and that PrP-interacting
risk factors may be involved in the slow or rapid
progression of AD pathology.
MATERIALS AND METHODS
The brain samples were provided by the
Prion Disease Surveillance Units of Germany
and Spain including, i.e., spAD, rpAD, spo-
radic Creutzfeldt–Jakob disease (sCJD), and non-
demented control cohorts as described previously [8].
Human samples from Spain were obtained follow-
ing the Spanish legislation (Ley de la Investigación
Biomédica 2013 and Real DecretoBiobancos, 2014)
and the approval of the local ethics committees. All
experimental protocols were approved and the study
conformed to the Code of Ethics of the World Med-
ical Association. All study participants or their legal
next of kin gave informed consent and the study was
approved by the local ethics committee in Göttingen
(No. 24/8/12). All samples were anonymized with
regard to at personal data and are summarized in
Table 1).
Brain tissue samples were processed as demon-
strated previously [8, 21]. Briefly, frontal cortex area
28 was taken from spAD cases (8M/5F) with mean
age of 75 years, rpAD cases (5M/4F) with mean age
of 69 years, and age-matched non-demented controls
(8M/2F). Sucrose velocity gradient ultracentrifuga-
tion was performed as described previously with
slight modification [7]. Briefly, samples were homog-
enized by 10% w/v of tissue in 1x PBS containing 2%
w/v sarkosyl (pH 7.4). Homogenates were layered
onto the top of 10–45% sucrose continuous gradients.
Ultracentrifugation was performed at 50,000 rpm for
73 min at 5◦C and 20 fractions were collected from
top to bottom.
Frozen and paraffin-embedded tissue sections
were processed and immunofluorescence and con-
focal laser scanning microscopy was performed as
described previously [8, 22]. Anti-PrP 3F4 (1 : 200),
anti-PrP SAF70 (1 : 250), anti- ZAG (1 : 100),
Alexa 488/546 conjugated anti-rabbit (1 : 200),
and TO-PRO-3 iodide were used. Tissue lysis,
immunoblotting co-immunoprecipitation were per-
formed as described previously [8].
Furthermore, we performed in-gel tryptic diges-
tion leading to peptide sequence analysis. Briefly,
specific bands were excised from silver-stained 1-
DE gel into 1-2 mm2 slices. Slices were then washed
in ddH2O, reduced with 10 mM dithiothreitol by
incubating for 30 min at 56◦C, and alkylated with
55 mM idoacetamide at room temperature in dark
for 60 min. Gel slices were then washed in ace-
tonitrile (ACN) for 15 min and dried in a SpeedVac
to remove excess solvent. Protease cleavage was
done by rehydrating dried gel slices with the mini-
mum amount of porcine trypsin solution (12.5 ng/l
in 0.025 M aqueous ammonium bicarbonate) for
overnight at 37◦C. After tryptic digestion, gel slices
were incubated with 10 l ddH2O for 15 min at 37◦C
followed by addition of 80 l ACN and incubation
for 15 min at 37◦C. Supernatant was taken after a
short spin. Residual peptides were dissolved from
gel slices by vortex and incubation in 65 l 5%
formic acid for 15 min at 37◦C. ACN 65 l was
added and further incubated for 15 min at 37◦C.
Supernatant was collected after a short spin and
added to supernatant from the previous step. Com-
bined supernatant was evaporated to dryness in a
vacuum concentrator. Dried samples were dissolved
in 10 l of 30% ACN and 0.1% triflouroacetic
acid.
For mass spectrometric analysis, peptide mix-
tures were concentrated on a Reversed Phase-C18
precolumn (0.15 mm ID x 20 mm, self-packed
with Reprosil-Pur 120 C18-AQ 3 m material) fol-
lowed by separation using Reversed Phase-C18
nanoflow chromatography (Picofrit column, 0.07
5 mm ID × 200 mm (New Objective, Woburn, USA))
using a 15 min linear gradient on an Easy nLC-1000
nanoflow chromatography system (Thermo Fisher
Scientific, Dreieich, Germany). Eluents were ana-
lyzed on a Q Exactive hybrid quadrupole/orbitrap
mass spectrometry system operated under Excalibur
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Table 1
Patient details: Summary of cases used in the present study
No. Patient ID Gender Age Disease Braak Postmortem
duration (y) stages (AD) delays (h)
1 rpAD1 Male 70 <4 VI/C 11 : 30
2 rpAD2 Male 76 <4 VI/C 06 : 30
3 rpAD3 Female 76 <4 VI/C 18 : 00
4 rpAD4 Female 77 <4 IV/A 12 : 00
5 rpAD5 Male 78 <4 V/C 03 : 30
6 rpAD6 Female 79 <4 V 05 : 30
7 rpAD7 Female 81 <4 III/B 06 : 00
8 rpAD8 Male 83 <4 VI/C 05 : 30
9 rpAD9 Male 83 <4 V/C 08 : 20
10 spAD1 Female 56 >4 V/C 07 : 00
11 spAD2 Male 64 >4 II/A 06 : 00
12 spAD3 Female 67 >4 III/C 06 : 10
13 spAD4 Male 69 >4 III/0 13 : 10
14 spAD5 Female 71 >4 III/0 07 : 15
15 spAD6 Female 72 >4 V/C 09 : 30
16 spAD7 Female 75 >4 V/C 04 : 15
17 spAD8 Male 78 >4 V/C 09 : 30
18 spAD9 Female 82 >4 VI/B 01 : 45
19 spAD10 Male 83 >4 III/0 07 : 25
20 spAD11 Male 87 >4 V/C 07 : 05
21 spAD12 Female 90 >4 IV/A 09 : 55
22 spAD13 Female 93 >4 V/C 03 : 00
23 sCJD 1 Female 72 <1 – 06 : 00
24 sCJD 2 Male 79 <1 – 09 : 45
25 sCJD 3 Female 60 <1 – 07 : 50
26 sCJD 4 Male 46 <1 – 07 : 00
27 sCJD 5 Female 65 <1 – 05 : 05
28 sCJD 6 Male 83 <1 – 11 : 00
29 sCJD 7 Male 76 <1 – 04 : 50
30 sCJD 8 Male 64 <1 – 11 : 30
31 Cont 1 Male 69 – II/A 05 : 03
32 Cont 2 Male 68 – I/0 05 : 03
33 Cont 3 Female 64 – I/0 09 : 00
34 Cont 4 Male 67 – I/0 05 : 03
35 Cont 5 Male 74 – II/A 11 : 00
36 Cont 6 Male 86 – II/A 06 : 45
37 Cont 7 Female 73 – I/0 04 : 03
38 Cont 8 Male 70 – I/A 09 : 00
39 Cont 9 Male 61 – I/0 03 : 03
40 Cont 10 Male 77 – I/A 11 : 00
Disease duration less than four years (<4) consider as rapid forms and more than four year (>4) considered as slow
forms of AD. rpAD, rapid progressive Alzheimer’s disease; spAD, slow progressive classical Alzheimer’s disease;
sCJD, Creutzfeldt-Jakob disease; Cont, control (non-demented).
v2.4 software (Thermo Fisher Scientific). Analysis
was carried by a Top10 method in the Data
Dependent Acquisition mode. Tandem mass spec-
tra were extracted for database searching, using
Raw2MSM v1.17 software (Max Planck Institute
for Biochemistry, Martinsried, Germany). MS/MS
samples were analyzed using Mascot (Matrix Sci-
ence, London, UK; version 2.4.1) set for searching
UniProt/SwissProt database (release 02/14 filtered
for Homo sapiens entries) with 5 ppm mass tolerances
for precursors and 0.020 Da for fragments, respec-
tively. Methionine oxidation was used as a variable
modification and cysteine carbamidomethylation as a
fixed modification. Up to two missed cleavages were
allowed. Scaffold software v4.4.1.1 (Proteome Soft-
ware, Portland/OR, USA) was used for validation
of MS/MS based peptide and protein identifications.
Peptide identifications were accepted, if established
at greater than 95.0% confidence. While, a minimum
of two confident peptide identifications and a confi-
dence threshold of 99.0% were required for protein
identifications [23].
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Fig. 1. Characteristically distinct PrP isoforms in spAD and rpAD human brains. A) Localization of PrP and nuclear immunoreactivity
in the frontal cortex brain region in spAD, rpAD, and control brain tissues using SAF70 anti-PrP antibody. Zoom shows overlapping of
nucleus with PrP. ICA and scatter plots illustrate the colocalization pixel intensities between PrP and nucleus. B) PrP expression in spAD and
rpAD by using SAF70 anti-PrP antibody and immunoblotting analysis and beta actin as loading control. DG, di-glycosylated isoforms; MG,
mono-glycosylated isoforms; UG, un-glycosylated isoforms. C-E) Densitometry analysis from four independent (± SD) immunoblotting
experiments using 15 controls (Con), 15 spAD, and 8 rpAD cases. F) Immunoblots from 2-DE gels of controls, spAD and rpAD proteins,
using SAF70 anti-PrP antibody. Linear 7 cm IPG strips (pH 4–8) were used and loaded with 50 g of protein. Upper panels represent co-
localization points (ImageJ WCIF plugin) and lower panel represents co-localization and FRET index (ImageJ FRET plugin) of silver-stained
2-DE gels in spAD, rpAD, and controls. Pearson’s co-localization correlation co-efficient rp (–1 ≤ rp ≤ 1) experiments and FRET index were
generated by ImageJ (WCIF plugin) software. The significance was calculated with the one-way ANOVA Friedman test (∗p < 0.05) and AU
arbitrary units.
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Fig. 2. Separation of characteristically distinct PrP isoforms by sedimentation velocity in sucrose gradient in spAD and rpAD human brains.
A) Separation of PrP isoforms by sedimentation velocity in sucrose gradient. The gradient fractionation profile of PrP particles from spAD,
rpAD, sCJD, and controls after separation by ultracentrifugation in sucrose gradient. Fractions collected from the bottom of the tubes
were immunoblotted by anti-PrP mAb SAF70. B-E) Densitometry analysis from four independent (± SD) immunoblotting experiments in
15 controls (Con), 15 spAD, 8 rpAD cases, 15 sCJD, and 15 non-demented controls and graph was generated by Prism 5 software. The
significance was calculated with the one-way ANOVA Friedman test (∗p < 0.05) and AU arbitrary units.
RESULTS
Characteristic and distinct PrP isoforms in spAD
and rpAD human brains
The distinct PrP isoforms and aberrant localization
of PrP in spAD and rpAD brain may be characterized
by different phenotypes and binding domains or the
interplay of specific mechanisms during the disease
progression.
In this study, we found differential PrP immunore-
activity in the neuronal cell bodies of the frontal
cortex region of spAD brains, rpAD, and con-
trol brain tissues. PrP expression was significantly
increased in spAD and rpAD cases as compared
to controls. rpAD cases also showed significantly
weaker immunoreactivity as compared to spAD cases
(Fig. 1A). Notably, PrP showed aberrant localiza-
tion toward the nuclear region specifically in rpAD
as compared to age-matched controls (Fig. 1A).
The differential expression of PrP by one- and two-
dimensional immunoblot reveals a 1.2-fold (p ≤ 0.05)
decrease in rpAD as compared to the characteristic
isoforms of PrP in the post-translationally modified
di-glycosylated PrP isoforms (Fig. 1B-F). Colocal-
ization and the FRET index suggest that the rpAD
cases showed the significant decrease of PrP isoforms
at the size of 37 kDa (Fig. 1F).
To further characterize the hydrodynamic infor-
mation on the size and shape of PrP molecules in
rpAD as compared to spAD and controls, we used
a high-speed ultra-centrifugation and sucrose gradi-
ent to evaluate the sedimentation velocity. We also
used sCJD cases as PrP controls in this sedimen-
tation assay to check for a possible overlap of PrP
isoforms between rpAD and CJD cases. The PrP in
the brain tissue of controls, spAD, rpAD, and sCJD
cases remained in the top (1–6) fractions, as expected
for monomers or dimers of PrP (Fig. 2). However, a
broad range of densities and a variable fraction (7–12)
remained floating in spAD and rpAD cases (Fig. 2C,
D). Interestingly, rpAD showed a distinct species of
PrP in the fraction (13, 14, and 16), similar to sCJD
cases (Fig. 2A, D, E). However, these fractions in
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rpAD were not proteinase K-resistant as compared
to sCJD (data not shown here).
Characteristic PrP interactome identification
in spAD and rpAD human brains
We isolated PrP-interacting partners from spAD,
rpAD, and controls by co-purification of PrP, using
Protein G coupled to super magnetic Dynabeads®
(Fig. 3A). Eluates from this co-immunoprecipitation
with SAF32 and SAF70 PrP were stained silver
(Fig. 3A) and whole lanes from spAD, rpAD, and
control eluate were excised and recovered with tryptic
in-gel/in-solution digestion. Proteins were identified
with ESI/Q-TOF MS/MS. Both known and novel
PrP-interacting partners were among the proteins
identified in this study (Table 2). The ESI/Q-TOF
MS/MS identified proteins based on protein iden-
tification probability, the exclusive unique peptide
count, and total spectrum count; the spectrum and
sequence are summarized in Supplementary Table 1
listing fifteen proteins as interacting partners of PrP.
Of these fifteen proteins, two—histone H2B type 1-
B (H2B-1B) and zinc alpha-2 protein (ZAG)—were
specifically bound with PrP isolated from rpAD
cases. Furthermore, three proteins, i.e., tubulin beta
2C, synaptojanin-1, and synaptopodin, showed no
potential interaction with the PrP isoform from spAD
and rpAD cases, and appeared to bind with con-
trols. Interestingly, one protein, myelin P2, was
alone isolated as the binding partner with the PrP
isoform in AD samples. Four interacting proteins,
i.e., peroxiredoxin–1, four-and-half LIM domains
protein 1, transketolase variant (fragment), and the
basic myelin protein, were commonly found in AD
and rpAD cases. Four interacting proteins, namely
ribonuclease UK114, fructose-bisphosphate aldolase
A and lysozyme C, were found in common in AD and
non-demented healthy controls; and lastly, synapsin-
1 and myelin proteolipid proteins were found to
interact with PrP in all cases.
ZAG and PRDX1 were further validated by
immunoblotting after reverse and co-immunopre-
cipitation. We used ZAG and PRDX1 proteins as
bait protein under non-denaturing conditions and
were able to isolate (prey) PrP protein only in
rpAD brain samples from specifically ZAG-bind-
ing complex (Fig. 3B-D). This immunoprecipitation
and reverse co-immunoprecipitation were performed
under physiological conditions and proteins were
post-translationally modified and conformationally
natural. Additionally, we used PrDX1 as bait and
managed to isolate PrP from both AD disease
subtypes (spAD and rpAD). Isolated PrP and
immunoblotting showed no signal from control brain
samples (Fig. 3B).
Furthermore, we performed co-localization analy-
sis by using confocal laser scanning microscopy and
demonstrated that ZAG specifically and significantly
showed increased co-localization with PrP in rpAD
in the cortex region of the brain in contrast to spAD
and controls groups (Fig. 3F). Use of ICA and scatter
plots highlight the interaction between PrP and ZAG
in rpAD brain samples (Fig. 3F a-f). We could also
predict the molecular interactions by using the com-
putational protein docking program ZDOCK to look
for possible interaction sites between PrP and ZAG,
which we indeed found (Fig. 3E).
DISCUSSION
The emerging field of proteomics and protein-
protein interaction complexes can provide important
insights into disease mechanisms. Recent studies
using genome-wide protein expression by microar-
rays successfully predicted the disease outcome of a
patient by correlating human interactome data [24].
In this study, we were able to successfully isolate
PrP-interacting proteins from patients with hetero-
geneous AD during disease progression. This study
clearly demonstrates a differential expression and
Fig. 3. Characteristic PrP interactome identification in spAD and rpAD human brains. PrP-interacting partners isolated from spAD, rpAD,
and control cases by using SAF32 and SAF70 PrP Protein G coupled to super magnetic Dynabeads. The bands were excised, in-gel digested,
and proteins were identified by ESI/Q-TOF MS/MS analysis. A) IP eluates were stained silver, illustrating the PrP-interacting proteins in
spAD, rpAD, and controls. B) IP eluates were immunoblotted against PrP and ZAG by using specific monoclonal antibodies. ZAG and
GAPDH immunoblotting analysis in spAD, rpAD, and control samples were used as loading controls. C, D) Densitometry analysis from
four independent (± SD) IP eluates immunoblotting experiments with15 controls (Con), 15 spAD, and 8 rpAD cases each. The significance
was calculated with the one-way ANOVA Friedman test (∗p < 0.05) and AU arbitrary units. E) Bioinformatic protein-protein prediction
shows PrP (grey) and ZAG (pink) interacting sites by ZDOCK 3.0, and the molecule represents its corresponding centered orientation. F)
Co-localization of PrP and ZAG in the frontal cortex brain region of spAD, rpAD, and control brain tissues using SAF70 anti-PrP antibody
(red signal) and ZAG antibody (green signal). Zoom shows overlapping (yellow signal) of PrP and ZAG in the frontal cortex brain region
of spAD, rpAD, and control brains. ICA (a, c, e) and scatter plots (b, d, f) illustrate the interaction between PrP and ZAG in rpAD brain
samples.
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Table 2
List of prion protein interacting proteins in rpAD and spAD by using ESI/MS analysis
No. Protein Name Disease Accession Localization Relevance Relevance PrP ligand
Specific No. (UniProt) (AD) (Prion)
1 Histone H2B type 1-B rpAD P33778 Nu Known [26] Known [30] Novel
2 Zinc alpha-2 protein rpAD P25311 Nu, Pm, Ee Known [31] Novel Novel
3 Peroxiredoxin–1 rpAD and AD Q06830 Nu, C, Ee Known [32–37] Known [28, 38] Known [28]
4 Four and a half LIM domains protein 1 rpAD and AD Q13642 C, Nu, Pm, Fa Known [43] Known [43] Known [44]
5 Transketolase variant (Fragment) rpAD and AD Q53EM5 – Known [45–49] Known [50] Novel
6 Myelin basic protein rpAD and AD P02686 Mm, Cs Known [39, 51–54] Known [55, 56] Novel
7 Myelin P2 AD P02689 C, Ee, Ms Known [57, 58] Known [59] Novel
8 Tubulin, beta 2C Cont Q8IZ29 C Known [60, 61] Known [28, 62] Known [28]
9 Synaptojanin – 1 Cont O43426 C, Cp Known [63–66] Known [67] Novel
10 Synaptopodin Cont. Q8N3V7 C, Ck, Cj Known [68–70] Novel Novel
11 Ribonuclease UK114 AD and Cont P52758 C, Nu Known [71] Known [72] Novel
12 Fructose-bisphosphate aldolase A AD and Cont P04075 C Known [37, 61] Known [28, 73–75] Known [28]
13 Lysozyme C AD and Cont P61626 S, Ee Known [76] Known [77] Novel
14 Synapsin-1 all P17600 Cj, Ga, Sv Known [68–70] Known [78–80] Known [81]
15 Myelin Proteolipid protein all P60201 Ms, Pm Known [39–41] Novel Known [42]
rpAD, rapid progressive Alzheimer’s disease; AD, slow progressive classical Alzheimer’s disease; Cont, control (non-demented); Nu,
nucleus; Pm, plasma membrane; Ee, extracellular exosome; C, cytoplasm; Ms, myelin sheath; Fa, focal adhesion; Mm, myelin membrane;
Cs, cytoplasmic side; Cm, cell membrane; Cp, clathrin coat of coated pit; Cj, cell junction, Ck, cytoskeleton; S, secreted; Ga, Golgi apparatus;
Sv, synaptic vesicle.
The localization of proteins and accession number is assigned as in ExPASy protein database and Uniprot data base. Relevance with AD,
prion and PrP ligand were established by deep NCBI literature database search. Tandem mass spectra were extracted and all samples were
analyzed using Mascot (Matrix Science, London, UK; version 2.3.02). Mascot was set up to search the uniprot human database and used
trypsin enzyme for protein digestion. Mascot was searched with a fragment ion mass tolerance of 0.60 Da and a parent ion tolerance of 10.0
PPM. Methyl of lysine and arginine, oxidation of Methionine, dimethyl of lysine and arginine, acetyl of lysine, trimethyl of lysine were
specified as variable modifications, whereas carbamidomethyl of cysteine was specified as fixed modification in Mascot database search. For
protein identification Scaffold (version Scaffold 4.4.7, Proteome Software Inc., Portland, OR) was used to validate MS/MS based peptide
and protein identifications. Peptide identifications were accepted if probability by the Peptide Prophet algorithm showed greater than 96.0%
[31], greater than 95.0% probability and at least 2 identified peptides.
localization of PrP in the rpAD brain as compared
to the brains of spAD patients.
In spAD and rpAD cases, the differences in
PrP expression, localization, and particle size may
influence tissue-specific complexes and their asso-
ciated cellular signaling pathways. Lately it has
also been demonstrated that PrP binds with A
in AD patients, and exosomal PrP neutralizes the
neurotoxicity caused by A through the fibrilliza-
tion mechanism [19, 25]. We were able to isolate
PrP-interacting protein complexes, demonstrating a
number of novel interacting proteins involved in AD
pathology. We also identified several proteins already
known to contribute to the disease pathology, which
confirms the validity of our data. Other novel proteins
were identified with a disease-specific contribution.
Interestingly, two proteins—H2B-1B and
ZAG—showed potential interaction with PrP,
specifically in rpAD cases. H2B-1B has already
been studied in AD cases in relation to damage to
DNA and cell cycle activation, and it is critical for
rapid p53-mediated cell cycle inhibition, caspase-3
activation, and for inducing the phosphorylation of
histone leading to cell death [26]. ZAG is a 40 kDa
glycoprotein; one study shows that the relevance
of ZAG in dementia is the differentially regulated
cerebrospinal fluid protein in frontotemporal demen-
tia patients [27]. It is interesting to note that one
protein, myelin P2, was isolated as a binding partner
with the PrP isoform in spAD samples, suggesting a
possible link with spAD cases.
Furthermore, our data set demonstrates that
three proteins, ribonuclease UK114, fructose-
bisphosphate aldolase A, and lysozyme C, specif-
ically interact with PrP isolated from spAD and
controls. Fructose-bisphosphate aldolase A is known
as binding partner of the cellular form of PrP [28]
and has also been reported to be significantly upregu-
lated in the cerebrospinal fluid of sCJD (human prion
disease), but not in AD [29]. There was no regula-
tory response observed in the brains of CJD and AD
cases [29]. The involvement of fructose-bisphosphate
aldolase A in CJD and rpAD cases demonstrates a
similarly rapidly progressive mechanism in both dis-
eases.
Our interactomic approach includes a list of known
and novel PrP-interacting proteins. Several proteins
identified in this study are unique in relation to AD
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and its various forms, and are crucial for various cel-
lular pathways. Determining this translational aspect
of disease progression is of importance in further
understanding the slow or fast progression of AD.
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